Igia Pharmaceuticals, Inc (IGIA), is a privately held rare disease pharmaceutical development company incorporated in Delaware with main offices in Florence, Kentucky (just south of Cincinnati.) Igia was created in March 2017 to develop products for the treatment of orphan and small population indications with unmet medical needs.
Currently the company is repurposing the CML drug Dasatinib (IG-100), an orally bioavailable inhibitor of multiple signaling kinases, for the treatment of Noonan syndrome-associated cardiac dysfunction in pediatric patients 6 months of age and older.
At the request of the Food and Drug Administration, Igia Pharmaceuticals has done additional testing to confirm the doses that will have the best chance of success, and has applied to initiate a clinical study in infants with the more severe forms of the disease.
The company will begin a Phase 2A trial in Q1 2021, to establish initial safety and pharmacology that will be used to fast track IG-100 via 505(b)(2).
Currently the company is repurposing the CML drug Dasatinib (IG-100), an orally bioavailable inhibitor of multiple signaling kinases, for the treatment of Noonan syndrome-associated cardiac dysfunction in pediatric patients 6 months of age and older.
At the request of the Food and Drug Administration, Igia Pharmaceuticals has done additional testing to confirm the doses that will have the best chance of success, and has applied to initiate a clinical study in infants with the more severe forms of the disease.
The company will begin a Phase 2A trial in Q1 2021, to establish initial safety and pharmacology that will be used to fast track IG-100 via 505(b)(2).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Kentucky
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Orphan/Rare Diseases
Lead Product in Development:
IG-100
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
